Ancora Heart

Ancora Heart is a private, clinical-stage medical device company pioneering a novel, minimally invasive approach to treating heart failure. Its lead product, the AccuCinch Ventricular Restoration System, is the first percutaneous device designed to directly remodel the dilated left ventricle, targeting the underlying structural pathology of HFrEF. The company is currently advancing the technology through the pivotal CORCINCH-HF study, a global randomized controlled trial. With FDA Breakthrough Device Designation, Ancora Heart is positioned to address a significant unmet need in a large, chronic patient population with high morbidity and mortality.

Percutaneous ventricular restoration via a transcatheter anchor-and-cinch system to directly remodel and reduce the volume of the dilated left ventricle in heart failure.

Competition includes pharmaceutical heart failure drugs, cardiac resynchronization therapy devices, transcatheter mitral valve repair systems, and invasive surgical options like LVADs and transplant. However, no other percutaneous device directly restores the left ventricle's structure, giving AccuCinch a potentially unique mechanistic and clinical niche.